These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 31188771

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Giant cell tumour of bone in the denosumab era.
    van der Heijden L, Dijkstra PDS, Blay JY, Gelderblom H.
    Eur J Cancer; 2017 May; 77():75-83. PubMed ID: 28365529
    [Abstract] [Full Text] [Related]

  • 23. The role of Denosumab in joint preservation for patients with giant cell tumour of bone.
    Perrin DL, Visgauss JD, Wilson DA, Griffin AM, Abdul Razak AR, Ferguson PC, Wunder JS.
    Bone Joint J; 2021 Jan; 103-B(1):184-191. PubMed ID: 33380180
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Short-term Preoperative Denosumab With Surgery in Unresectable or Recurrent Giant Cell Tumor of Bone.
    Zhang RZ, Ma TX, Qi DW, Zhao M, Hu T, Zhang GC.
    Orthop Surg; 2019 Dec; 11(6):1101-1108. PubMed ID: 31762217
    [Abstract] [Full Text] [Related]

  • 27. Role of (Neo)adjuvant Denosumab for Giant Cell Tumor of Bone.
    Palmerini E, Staals EL, Jones LB, Donati DM, Longhi A, Randall RL.
    Curr Treat Options Oncol; 2020 Jul 04; 21(8):68. PubMed ID: 32623530
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Preoperative denosumab treatment with curettage may be a risk factor for recurrence of giant cell tumor of bone.
    Sano K, Suehara Y, Okubo T, Sasa K, Kurihara T, Akaike K, Kubota D, Torigoe T, Hasegawa N, Ishii M, Nakamura Y, Kim Y, Takagi T, Kaneko K, Hayashi T, Saito T.
    J Orthop Surg (Hong Kong); 2020 Jul 04; 28(2):2309499020929786. PubMed ID: 32539628
    [Abstract] [Full Text] [Related]

  • 30. [Clinical, radiologic and pathologic features of giant cell tumor of bone treated with denosumab].
    Gong LH, Liu WF, Ding Y, Zhang W, Yang YK, Yu F, Wong GQ, Huang XY, Niu XH.
    Zhonghua Bing Li Xue Za Zhi; 2018 Jun 08; 47(6):449-454. PubMed ID: 29886590
    [Abstract] [Full Text] [Related]

  • 31. The current standing on the use of denosumab in giant cell tumour of the bone.
    Singh VA, Puri A.
    J Orthop Surg (Hong Kong); 2020 Jun 08; 28(3):2309499020979750. PubMed ID: 33331233
    [Abstract] [Full Text] [Related]

  • 32. The efficacy and safety of short-course neoadjuvant denosumab for en bloc spondylectomy in spinal giant cell tumor of bone: a preliminary report.
    Tang Q, Lu J, Zhu X, Song G, Wu H, Xu H, Wang A, Wang J.
    Eur Spine J; 2023 Dec 08; 32(12):4297-4305. PubMed ID: 37318598
    [Abstract] [Full Text] [Related]

  • 33. Denosumab-treated giant cell tumor of bone. Its histologic spectrum and potential diagnostic pitfalls.
    Roitman PD, Jauk F, Farfalli GL, Albergo JI, Aponte-Tinao LA.
    Hum Pathol; 2017 May 08; 63():89-97. PubMed ID: 28235628
    [Abstract] [Full Text] [Related]

  • 34. Preoperative Cytoreduction of Clival Giant Cell Tumor: An Effective Replication of the Systemic Modality in the Skull Base.
    Sekar A, Rudrappa S, Gopal S, Ghosal N, Gupta V, Ts L.
    World Neurosurg; 2018 Nov 08; 119():97-102. PubMed ID: 30075260
    [Abstract] [Full Text] [Related]

  • 35. Clinical, radiological and pathological outcomes following treatment of primary giant cell tumour of bone with Denosumab.
    Murphy B, Vodanovich D, Spelman T, Gullifer J, Slavin J, Powell G, Pang G, Choong P.
    ANZ J Surg; 2020 Dec 08; 90(12):2553-2558. PubMed ID: 32767541
    [Abstract] [Full Text] [Related]

  • 36. Challenges of denosumab in giant cell tumor of bone, and other giant cell-rich tumors of bone.
    Lipplaa A, Dijkstra S, Gelderblom H.
    Curr Opin Oncol; 2019 Jul 08; 31(4):329-335. PubMed ID: 30844887
    [Abstract] [Full Text] [Related]

  • 37. Comparison of Denosumab and Zoledronic acid as neoadjuvant therapy in patients with giant cell tumor of bone.
    Kanwat H, Banjara R, Kumar VS, Majeed A, Gamnagatti S, Khan SA.
    J Orthop Surg (Hong Kong); 2021 Jul 08; 29(2):23094990211007565. PubMed ID: 34231432
    [Abstract] [Full Text] [Related]

  • 38. Denosumab does not decrease the risk of lung metastases from bone giant cell tumour.
    Tsukamoto S, Mavrogenis AF, Leone G, Righi A, Akahane M, Tanzi P, Kido A, Honoki K, Tanaka Y, Donati DM, Errani C.
    Int Orthop; 2019 Feb 08; 43(2):483-489. PubMed ID: 30099641
    [Abstract] [Full Text] [Related]

  • 39. Conversion in a Resectable Tumor after Denosumab Neoadjuvant in a Large Dorsal Giant Cells Tumor: A Case Report and a Literature Review.
    Sereno M, Franco SR, de la Reina L, Campo-Cañaveral de la Cruz JL, Muñoz de Legaría M, Casado Saénz E.
    Curr Oncol; 2023 Oct 21; 30(10):9335-9345. PubMed ID: 37887575
    [Abstract] [Full Text] [Related]

  • 40. Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series.
    Girolami I, Mancini I, Simoni A, Baldi GG, Simi L, Campanacci D, Beltrami G, Scoccianti G, D'Arienzo A, Capanna R, Franchi A.
    J Clin Pathol; 2016 Mar 21; 69(3):240-7. PubMed ID: 26338802
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.